NO20071258L - Imidazolforbindelser. - Google Patents

Imidazolforbindelser.

Info

Publication number
NO20071258L
NO20071258L NO20071258A NO20071258A NO20071258L NO 20071258 L NO20071258 L NO 20071258L NO 20071258 A NO20071258 A NO 20071258A NO 20071258 A NO20071258 A NO 20071258A NO 20071258 L NO20071258 L NO 20071258L
Authority
NO
Norway
Prior art keywords
imidazole
ring
carbamoyl
alkyl
optionally substituted
Prior art date
Application number
NO20071258A
Other languages
English (en)
Inventor
Tatsuya Watanabe
Mari Kusama
Toshihiro Hosaka
Yuko Kubota
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20071258L publication Critical patent/NO20071258L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives en Imidazolforbindelse av formel: hvor ring A er benzen eller en heterosyklisk ring; G er alkyltio, alkylsulfonyl, valgfritt substituert fenyl, eller valgfritt substituert heterosyklisk ring gruppe, etc; Ring C er imidazol; R1 er karbamoyl, etc; R2ercyano, nitro, hydroksyl, alkoksy, halogen, karboksy, alkoksykarbonyl, karbamoyl, amino, alkyl, etc; M er 0 til 2; og R4 er hydrogen, alkyl, etc, eller et farmasøytisk akseptabelt salt derav, som er en stor konduktans kalsiumaktivert K-kanalåpner nyttig for behandling av polakisuri, urininkontinens, etc
NO20071258A 2004-09-17 2007-03-08 Imidazolforbindelser. NO20071258L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2004270603 2004-09-17
JP2004291188 2004-10-04
US61558904P 2004-10-05 2004-10-05
JP2004348137 2004-12-01
JP2005191064 2005-06-30
PCT/JP2005/017540 WO2006030977A2 (en) 2004-09-17 2005-09-16 Imidazole derivatives as large conductance calcium-activated k channel openers

Publications (1)

Publication Number Publication Date
NO20071258L true NO20071258L (no) 2007-06-18

Family

ID=38955179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071258A NO20071258L (no) 2004-09-17 2007-03-08 Imidazolforbindelser.

Country Status (10)

Country Link
US (1) US20080009506A1 (no)
EP (1) EP1799650A2 (no)
KR (1) KR20070052351A (no)
CN (1) CN101039916A (no)
AR (1) AR054083A1 (no)
AU (1) AU2005283294A1 (no)
CA (1) CA2580033A1 (no)
NO (1) NO20071258L (no)
TW (1) TW200616969A (no)
WO (1) WO2006030977A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
CA2750565C (en) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
NO2686520T3 (no) 2011-06-06 2018-03-17
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2013055793A1 (en) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
CN103582163B (zh) * 2012-08-01 2018-10-23 中兴通讯股份有限公司 承载处理方法、承载释放方法、装置及系统
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
WO2023009347A1 (en) * 2021-07-30 2023-02-02 The Regents Of The University Of California Compounds for modulating epithelial 15-(s)-lipoxygenase-2 and methods of use for same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
CN100540538C (zh) * 2001-04-16 2009-09-16 田边三菱制药株式会社 高传导率钙-活化k通道开启剂
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
EP1400243A1 (en) * 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US20070043084A1 (en) * 2003-05-08 2007-02-22 Astellas Pharma Inc. 1,2-Diarylimidazoles useful as inhibitors of cox
EP1675585A2 (en) * 2003-10-17 2006-07-05 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener

Also Published As

Publication number Publication date
KR20070052351A (ko) 2007-05-21
WO2006030977A3 (en) 2006-07-13
CN101039916A (zh) 2007-09-19
TW200616969A (en) 2006-06-01
AR054083A1 (es) 2007-06-06
US20080009506A1 (en) 2008-01-10
CA2580033A1 (en) 2006-03-23
EP1799650A2 (en) 2007-06-27
AU2005283294A1 (en) 2006-03-23
WO2006030977A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
NO20043587L (no) Nye heterocykliske forbindelser som er aktive som inhibitorer av beta-laktamaser
DE60328010D1 (de) Heterocyclische verbindungen
NO20070731L (no) Heterocykliske forbindelser.
WO2005011646A3 (en) Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
PE20120403A1 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
EA200801381A1 (ru) Производные пиримидина
TNSN08407A1 (en) Organic compounds
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20060219L (no) Forbindelser
NO20054852L (no) GFAT inhibitorer
WO2006030977A3 (en) Imidazole derivatives as large conductance calcium-activated k channel openers
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
NO20063621L (no) Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet
WO2006066133A3 (en) Histone deacetylase inhibitors
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
UY29709A1 (es) "compuestos quimicos"
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application